Valeritas touts new data for insulin delivery device

Valeritas (NSDQ:VLRX) touted data today from two new studies of its V-Go wearable insulin delivery device in patients with Type II diabetes. In one three-month evaluation of 60 people with Type II diabetes, researchers assessed if using V-Go could improve glycemic control in patients who were uncontrolled on prior treatment regimens.

Source: Valeritas touts new data for insulin delivery device

About the Author

Stephanie Figon, MS, RDN, LD

Founder of NutriScape.NET. As a dietitian since 1992, Steph Figon has had experiences in consulting, 15 years in clinical, and has operated a private practice nutrition counseling office for since 2011. The RDNutriScape Instagram